10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2021 | |||
CONSOLIDATED STATEMENTS OF EARNINGS | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 9, 2022) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Total Revenues | $ 46,385 | 42,518 | 26,145 |
| Cost of products sold | 9,940 [1] | 11,773 | 8,078 |
| Marketing, selling and administrative | 7,690 | 7,661 | 4,871 |
| Research and development | 11,354 | 11,143 | 6,148 |
| IPRD charge - MyoKardia acquisition | 0 | 11,438 | 0 |
| Amortization of acquired intangible assets | 10,023 | 9,688 | 1,135 |
| Other (income)/expense, net | (720) | (2,314) | 938 |
| Total Expenses | 38,287 | 49,389 | 21,170 |
| Earnings/(Loss) Before Income Taxes | 8,098 | (6,871) | 4,975 |
| Provision for Income Taxes | 1,084 | 2,124 | 1,515 |
| Net Earnings/(Loss) | 7,014 | (8,995) | 3,460 |
| Noncontrolling Interest | 20 | 20 | 21 |
| Net Earnings(Loss) Attributable to BMS | 6,994 | (9,015) | 3,439 |
| Earnings per common share attributable to BMS, basic (in usd per share) | 3.15 | (3.99) | 2.02 |
| Earnings per common share attributable to BMS, diluted (in usd per share) | 3.12 | (3.99) | 2.01 |
| Principal Transaction Revenue, Description of Reporting Category | |||
| Net product sales | |||
| Total Revenues | 45,055 | 41,321 | 25,174 |
| Alliance and other revenues | |||
| Total Revenues | 1,330 | 1,197 | 971 |
| [1] Excludes amortization of acquired intangible assets. | |||
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2021 | |||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS) | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 9, 2022) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Net Earnings/(Loss) | $ 7,014 | (8,995) | 3,460 |
| Other Comprehensive Income/(Loss), net of taxes and reclassifications to earnings: | |||
| Derivatives qualifying as cash flow hedges | 415 | (256) | (32) |
| Pension and postretirement benefits | 206 | (75) | 1,203 |
| Marketable debt securities | (9) | 5 | 36 |
| Foreign currency translation | (41) | 7 | 35 |
| Total Other Comprehensive Income/(Loss) | 571 | (319) | 1,242 |
| Comprehensive Income/(Loss) | 7,585 | (9,314) | 4,702 |
| Comprehensive Income Attributable to Noncontrolling Interest | 20 | 20 | 21 |
| Comprehensive Income/(Loss) Attributable to BMS | 7,565 | (9,334) | 4,681 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2021 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 9, 2022) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Cash Flows From Operating Activities: | |||
| Net Earnings/(Loss) | $ 7,014 | (8,995) | 3,460 |
| Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities: | |||
| Depreciation and amortization, net | 10,686 | 10,380 | 1,746 |
| Deferred income taxes | (1,393) | 983 | (924) |
| Stock-based compensation | 583 | 779 | 441 |
| Impairment charges | 1,207 | 1,203 | 199 |
| Pension settlements and amortization | 35 | 43 | 1,688 |
| Divestiture gains and royalties | (684) | (699) | (1,855) |
| IPRD charge - MyoKardia acquisition | 0 | 11,438 | 0 |
| Asset acquisition charges | 1,157 | 1,099 | 63 |
| Equity investment gains, net | (745) | (1,228) | (275) |
| Contingent consideration fair value adjustments | (542) | (1,757) | 523 |
| Other adjustments | 142 | (177) | (26) |
| Changes in operating assets and liabilities: | |||
| Receivables | (1,054) | (646) | 752 |
| Inventories | 13 | 2,672 | 463 |
| Accounts payable | 245 | 188 | 229 |
| Rebates and discounts | 863 | 1,189 | 591 |
| Income taxes payable | (1,063) | (2,305) | 907 |
| Other | (257) | (115) | 228 |
| Net Cash Provided by Operating Activities | 16,207 | 14,052 | 8,210 |
| Cash Flows From Investing Activities: | |||
| Sale and maturities of marketable debt securities | 4,196 | 6,280 | 3,809 |
| Purchase of marketable debt securities | (5,478) | (4,172) | (3,961) |
| Proceeds from sales of equity investment securities | 2,579 | 129 | 167 |
| Capital expenditures | (973) | (753) | (836) |
| Divestiture and other proceeds | 748 | 741 | 15,685 |
| Acquisition and other payments, net of cash acquired | (1,610) | (13,084) | (24,777) |
| Net Cash Used in Investing Activities | (538) | (10,859) | (9,913) |
| Cash Flows From Financing Activities: | |||
| Short-term debt obligations, net | (160) | (267) | 131 |
| Issuance of long-term debt | 0 | 6,945 | 26,778 |
| Repayment of long-term debt | (6,022) | (2,750) | (9,256) |
| Repurchase of common stock | (6,287) | (1,546) | (7,300) |
| Dividends | (4,396) | (4,075) | (2,679) |
| Other | 641 | 542 | (53) |
| Net Cash (Used in)/Provided by Financing Activities | (16,224) | (1,151) | 7,621 |
| Effect of Exchange Rates on Cash, Cash Equivalents and Restricted Cash | (102) | 111 | (9) |
| Increase in Cash, Cash Equivalents and Restricted Cash | (657) | 2,153 | 5,909 |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Year | 14,973 | 12,820 | |
| Cash, Cash Equivalents and Restricted Cash at End of Year | 14,316 | 14,973 | 12,820 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2021 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2021 10-K (Filed: Feb 9, 2022) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2021 | Dec 31, 2020 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 13,979 | 14,546 |
| Marketable debt securities | 2,987 | 1,285 |
| Receivables | 9,369 | 8,501 |
| Inventories | 2,095 | 2,074 |
| Other current assets | 4,832 | 3,786 |
| Total Current Assets | 33,262 | 30,192 |
| Property, plant and equipment | 6,049 | 5,886 |
| Goodwill | 20,502 | 20,547 |
| Other intangible assets | 42,527 | 53,243 |
| Deferred income taxes | 1,439 | 1,161 |
| Marketable debt securities | 0 | 433 |
| Other non-current assets | 5,535 | 7,019 |
| Total Assets | 109,314 | 118,481 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term debt obligations | 4,948 | 2,340 |
| Accounts payable | 2,949 | 2,713 |
| Other current liabilities | 13,971 | 14,027 |
| Total Current Liabilities | 21,868 | 19,080 |
| Deferred income taxes | 4,501 | 5,407 |
| Long-term debt | 39,605 | 48,336 |
| Other non-current liabilities | 7,334 | 7,776 |
| Total Liabilities | 73,308 | 80,599 |
| Commitments and contingencies | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2021 and 3,484 in 2020, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2021 and 2020 | 292 | 292 |
| Capital in excess of par value of stock | 44,361 | 44,325 |
| Accumulated other comprehensive loss | (1,268) | (1,839) |
| Retained earnings | 23,820 | 21,281 |
| Less cost of treasury stock 747 million common shares in 2021 and 679 million common shares in 2020 | (31,259) | (26,237) |
| Total Bristol-Myers Squibb Company Shareholders Equity | 35,946 | 37,822 |
| Noncontrolling interest | 60 | 60 |
| Total Equity | 36,006 | 37,882 |
| Total Liabilities and Equity | 109,314 | 118,481 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2021 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |